{"id":"W4293083622","doi":"10.1200/jco.2022.40.17_suppl.lba5500","title":"ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; BRCA mutation; Clinical endpoint; Population; Oncology; Placebo; Ovarian cancer; PARP inhibitor; Cancer; Surgery; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001496208,0.001395148,0.001745671,0.0005753996,0.0003422916,0.0008037489,0.001034472,0.001737898,0.008831317],"category_scores_gemma":[0.001242139,0.0005561713,0.001417269,0.0003798319,0.0008555586,0.0008458436,0.0004257703,0.00250505,0.001244283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006991026,"about_ca_system_score_gemma":0.0009625229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001002249,"about_ca_topic_score_gemma":0.003622298,"domain_scores_codex":[0.9995418,0.0002530506,0.0000211557,0.00009082045,0.00003179499,0.00006136797],"domain_scores_gemma":[0.9994054,0.0001423407,0.0001687979,0.00005062291,0.00002807442,0.0002047731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9591093,0.01042893,0.0005735839,0.0006340134,0.0007887396,0.00003768123,0.00004345617,0.0003807231,0.004590819,0.0001882966,0.00145415,0.02177027],"study_design_scores_gemma":[0.9189659,0.076979,0.001745837,0.00003341982,0.0003186167,0.00004681034,0.00001391982,0.0004116276,0.0003456868,0.0001552081,0.0009693391,0.00001469169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775647,0.00660088,0.0009441069,0.0007698147,0.0005167219,0.00606957,0.00199396,0.0002790602,0.00526116],"genre_scores_gemma":[0.9813188,0.002244625,0.002083259,0.001911121,0.0003905076,0.005528837,0.001871533,0.0000366876,0.004614548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008831317,"threshold_uncertainty_score":0.0295437,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2784281856441137,"score_gpt":0.5579846632316603,"score_spread":0.2795564775875466,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}